argenx SE Investor Day Presentation Deck
Bullous Pemphigoid Disease Activity Improves with
Increasingly Selective IgG Therapies
argenx
Selectivity for IgG
IVlg
PLEX
Immuno
adsorption
(Protein A)
Trial
Phase 3 double-blind randomized trial
56 patients
High dose IVlg (5 days) + oral
corticosteroids
Case series
5 patients
PLEX (7-14 cycles) in 4-8 weeks
Two case series
27 patients*
Immunoadsorption (most 1 cycle)
* 4 recalcitrant BP, 3 first line with high disease activity, 20 severe or refractory
(1) Kasperkiewicz et al., J Am Acad Dermatol. 2014; (2) Hübner et al., J Dtsch Dermatol Ges. 2018
(3) Mazzi, Transfusion and Apheresis Science. 2003; (4) Amagai et al., J. Dermatol. Sci. 2017
●
●
Response
Clear therapeutic benefit
Stronger response in severe disease
Fast improvement
100% complete remission
70% prednisone dose reduction
Strong antibody reductions
68% complete remission
37% off oral corticosteroids
No need for second cycle in most
patients
Clinical evidence for the role of pathogenic autoantibodies in bullous pemphigoid
42View entire presentation